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Abstract The gastric H,K-adenosine triphosphatase
(ATPase) is the primary target for treatment of acid-
related diseases. Proton pump inhibitors (PPIs) are weak
bases composed of two moieties, a substituted pyridine
with a primary pKa of about 4.0 that allows selective
accumulation in the secretory canaliculus of the parietal
cell, and a benzimidazole with a second pKa of about 1.0.
Protonation of this benzimidazole activates these prodrugs,
converting them to sulfenic acids and/or sulfenamides that
react covalently with one or more cysteines accessible from
the luminal surface of the ATPase. The maximal pharma-
codynamic effect of PPIs as a group relies on cyclic
adenosine monophosphate–driven H,K-ATPase transloca-
tion from the cytoplasm to the canalicular membrane of the
parietal cell. At present, this effect can only be achieved
with protein meal stimulation. Because of covalent binding,
inhibitory effects last much longer than their plasma half-
life. However, the short dwell-time of the drug in the blood
and the requirement for acid activation impair their efficacy
in acid suppression, particularly at night. All PPIs give
excellent healing of peptic ulcer and produce good, but less
than satisfactory, results in reflux esophagitis. PPIs combined
withantibioticseradicateHelicobacter pylori, but success has
fallen to less than 80%. Longer dwell-time PPIs promise to
improve acid suppression and hence clinical outcome.
Potassium-competitive acid blockers (P-CABs) are another
class of ATPase inhibitors, and at least one is in develop-
ment. The P-CAB under development has a long duration of
action even though its binding is not covalent. PPIs with a
longer dwell time or P-CABs with long duration promise to
address unmet clinical needs arising from an inability to
inhibit nighttime acid secretion, with continued symptoms,
delayed healing, and growth suppression of H. pylori
reducing susceptibility to clarithromycin and amoxicillin.
Thus, novel and more effective suppression of acid secretion
would benefit those who suffer from acid-related morbidity,
continuing esophageal damage and pain, nonsteroidal anti-
inflammatory drug–induced ulcers, and nonresponders to
H. pylori eradication.
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Introduction
The two major types of acid-related disorders are peptic
ulcer disease (PUD) and gastroesophageal reflux disease
(GERD), although other extra-esophageal disorders are
ascribed to gastric acid reflux (eg, reflux laryngitis). The
target for treatment was and still is reduction of gastric
acidity. However, despite clinical and commercial success,
histamine-2 receptor antagonists (H2-RAs) have several
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the clinical setting. The H2-RAs are less effective for the
management of GERD and gastrointestinal (GI) bleeding
than for healing of PUD, and the rapid development of
tachyphylaxis limits their usefulness for long-term maintenance
treatment or high-dose intravenous use. The H2-RAs have been
largely supplanted by the proton pump inhibitors (PPIs) because
of greater efficacy and lack of pharmacologic tolerance. The
PPIs were found to be very effective for the management of
patients with erosive esophagitis, and a meta-analysis in 1997
confirmed their superiority to H2-RAs for the treatment of
GERD, particularly erosive esophagitis [1].
PPIs have also found a place in treatment of a wide
range of acid-related disorders, including nonerosive reflux
disease (NERD) and PUD, especially as treatment or
prophylaxis of GI injury caused by nonsteroidal anti-
inflammatory drugs (NSAID). PPIs have became established
as combination antisecretory treatment, together with antibiotic
therapy, for the eradication of Helicobacter pylori infection.
Furthermore, PPIs have become the standard of care in
patients with nonvariceal upper GI bleeding or for the
prevention of stress-related m u c o s a lb l e e d i n gi ni n t e n s i v e
care units.
H2-Histamine Receptor Antagonists and PPIs
The launch in 1979 of cimetidine (Tagamet; GlaxoSmithKline,
Philadelphia,PA)revolutionizedmedicaltreatmentofPUDand
GERD, for the first time providing relatively long-lasting
reduction of gastric acid secretion with healing of both gastric
and duodenal ulcers and some remission of the symptoms of
GERD. Cimetidine was followed by ranitidine (Zantac;
Boehringer Ingelheim, Ingelheim, Germany), famotidine
(Pepcid; Johnson & Johnson, New Brunswick, NJ), and
nizatidine (Axid; Eli Lilly Indianapolis, IN)—all of which
have an identical mechanism of action, namely reversible
inhibition of the histamine (H2) receptor on the acid-secreting
parietal cell of the stomach. These drugs have very similar
mechanisms of action. Famotidine is the most potent
commonly prescribed H2-RA, with about a 20-fold increase
in potency. H2-RAs result in short-lived inhibition of acid
secretion; the onset of inhibition occurs after about 4 h and
maximal inhibition after about 8 h, with return of acid
secretion after about 12 h, therefore requiring at least twice-
daily administration. Moreover, all these drugs exhibit
tolerance such that they lose about 50% of their efficacy over
a 7-day period (Fig. 1).
Figure 1 shows the effect of ranitidine given at night to
reduce nighttime GERD symptoms on days 1, 7, and 28;
intragastric pH is raised to greater than 5.0 by nighttime of
day 1, but reaches a level between 2.0 and 3.0 by day 28
[2]. Hence, this class of drug offers little likelihood of
improved GERD symptoms, because the tolerization to
ranitidine shown in Figure 1 is shared by all H2-RAs.
The discovery that PUD was largely the result of
infection with H. pylori revolutionized the treatment of
PUD, namely eradication of the infection either with triple
or quadruple therapy. Hence, H2-RAs are used to treat
symptomatic GERD, but are not used alone for PUD.
NSAID-induced PUD requires better acid inhibition for
treatment, and hence H2-RAs are not indicated with
concomitant NSAID use.
The synthesis of a novel secretory inhibitor, omeprazole
(Prilosec; AstraZeneca, Wilmington, DE), in 1978 and its
launch in 1989 in the United States further revolutionized
treatment of acid-related diseases. Omeprazole was the first
drug of the PPI class. Four more such PPIs are now on the
market: lansoprazole (Prevacid; Takeda Pharmaceuticals,
Osaka, Japan), pantoprazole (Protonix; Wyeth-Ayerst
Laboratories, Madison, NJ), rabeprazole (Aciphex; Eisai,
Tokyo, Japan), and esomeprazole (Nexium; AstraZeneca,
Wilmington, DE). Their mechanism of action is unique
and their target is the active gastric proton pump, the H,
K-ATPase. They are weak-base prodrugs and accumulate
in the unique, highly acidic canalicular space of the
active parietal cell, where the pH is less than 2.0. At this
pH, they are converted to the active form of the drug,
which then covalently binds to one or more cysteines
that are accessed from the luminal surface of the pump.
Thus the inhibition is long-lasting and no tolerance has
been observed with this class of drug. However, they
require the presence of acid secretion for accumulation
and activation, hence their action is meal-dependent.
Moreover, they have a relatively short plasma half-life of
about 2 h. Given this mechanism of action, the effect on
acid secretion is cumulative, increasing to steady state
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Fig. 1 The effect of nighttime administration of ranitidine, 300 mg,
on intragastric pH
438 Curr Gastroenterol Rep (2010) 12:437–447after 3 to 5 days of administration, because pumps that
are nonsecreting will not be inhibited whereas inhibited
pumps will stay inhibited. A typical intragastric pH
profile is shown for pantoprazole in Fig. 2.
The ability to progressively increase intragastric pH with
H2-RAs and PPIs resulted in a comprehensive meta-
analysis of the relationship between intragastric pH, healing
of duodenal and gastric ulcers, and treatment of GERD
immediately after the launch of omeprazole. This analysis
predicted that a pH greater than 4.0 for 16 h per day was
optimum for healing of GERD and a pH greater than 3.0
was optimum for healing of duodenal ulcers (Fig. 3).
The gastric H,K-ATPase has a half-life of 50 h, hence
about 25% of pumps are synthesized per day, at a rate of
about 1% per hour [3]. It also seems likely that this
synthesis has a circadian rhythm, with more pumps
synthesized at night than during the day. Thus, in the
morning, before breakfast, a theoretical maximal pool of
parietal cell H,K-ATPase is available for activation. Figure 2
illustrates the persistence of nighttime acid secretion with
PPI administration, most likely because of the presence of
de novo synthesized pumps that were never exposed to the
PPI.
One of the most recent PPIs to be approved by the Food
and Drug Administration (FDA) is esomeprazole, the S-
enantiomer of the chiral omeprazole. Esomeprazole is
viewed as the most effective PPI launched thus far. Its
effect on intragastric pH and pharmacokinetic profile as
compared to omeprazole, 20 mg, is shown in Fig. 4.
Figure 4 shows that esomeprazole, 40 mg, results in greater
elevation of intragastric pH and an increase in the plasma
residence time, whereas virtually no difference can be seen
between omeprazole, 20 mg, and esomeprazole, 20 mg.
Esomeprazole is now generally viewed as the PPI of choice
for treatment of GERD.
However, as is evident from the pH profile, even with
esomeprazole, 40 mg, acidity at night drops to pH 3 or less
for several hours. Clearly, this condition will result in
continuing damage and symptoms. The improvement in
intragastric pH with esomeprazole, 40 mg, can be ascribed
to the small extension of plasma residence allowing more
pumps to be inhibited. Even administering a PPI twice a
day does not ablate nighttime acid secretion. With once-
daily administration, about 70% of the pumps are inhibited,
and with twice-daily adminstration, 80% are inhibited, still
leaving 20% active pumps at steady state. Also, at night
intragastric pH is not buffered by food, so that pH drops to
about 1.0 in the absence of medication and to less than 3.0,
even with adminstration of esomeprazole, 40 mg.
In the past decade or so, it has become evident that these
drugs have not provided the optimum treatment for acid-
related diseases and that a new target has to be achieved,
namely a pH of 5.0 or above for close to 24 h per day, but
also with no excursion to intragastric pH less than 3.0.
Pharmacologic Considerations
Despite their undoubted success in clinical management of
patients with acid-related disorders, the currently approved
PPIs have several limitations that stem from their pharma-
cokinetics and mechanism of action. The effectiveness of
the initial antisecretory action of a PPI depends on the dose
and timing in relation to meals, the plasma half-life of the
PPI, and the state of activation of the parietal cell. The
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Fig. 2 The effect of morning administration of pantoprazole, 40 mg,
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30 min to 1 h before the first meal of the day, to ensure that
the proton pumps (H, K-ATPase) are maximally activated
in the parietal cell when the drug is available in the plasma.
Clinical Implications
Because the PPIs all have similar plasma half-lives of 1 to
2 h, any proton pumps that are synthesized after the plasma
level of the PPI falls below the relative threshold of 50 ng/
mL will not be blocked from secreting acid. All current
PPIs are short-acting drugs, which cannot control acid
secretion over the entire 24-hour period with a single dose.
It has been suggested that 30% of patients require twice-
daily dosing to obtain effective control of daytime and
nighttime symptoms [4]. A significant proportion of
patients being prescribed PPIs are not given the appropriate
advice and dosing instructions. In a study of 1046 US
primary care doctors, 36% did not give their patients advice
on when and how to take their medication [5]. Moreover, in
a survey of 173 patients with GERD taking delayed-release
PPI treatment, only 27% took their PPI correctly (up to
60 min before any meal of the day) and only 9.7% dosed
optimally (15–60 min before the first meal of the day) [6].
A PPI that could be administered independently of meals
would be likely to improve compliance and acceptability
for many patients.
Unmet Clinical Needs in the Patient with Acid-Related
Disorders
Thus, unmet clinical needs exist despite the apparent
benefits of currently approved delayed-release PPIs. Such
needs include serious challenges in GERD, several of
which are addressed here, and NERD, which is touched on
by implication. Space does not permit discussion of other
important areas, which include the need for improved acid
control for upper GI bleeding, nonvariceal and variceal
upper GI bleeding, and management and prevention of
stress-related mucosal damage in intravenous and oral
formulations [7]. Other important areas include the treat-
ment and prevention of NSAID-related upper GI injury,
which is acid-dependent. NSAIDs are usually given two or
more times per day, and a once-daily PPI does not
adequately control acid later in the day and at night (see
below) [8]. Similar arguments exist for the combination
therapy of PPIs with antibiotics for the optimal eradication
of H. pylori infection.
Unmet Needs in the Patient with GERD
A recent cross-sectional survey of 726 patients on long-
term PPIs (39% GERD) found that reflux symptoms
persisted in 59% of patients [9￿]. Our recent meta-analysis
of symptomatic GERD patients found that in about two
thirds of patients, reflux symptoms are not adequately
controlled after the first dose of a PPI, and nearly 50% of
patients still suffer symptoms 3 days later [10].
Erosive esophagitis healing is one important trial
endpoint, and a substantial proportion of patients do not
heal after standard doses of PPIs for 8 weeks. The weighted
healing rate for all grades of erosive esophagitis for five
marketed PPIs at standard doses for 8 weeks ranges from
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440 Curr Gastroenterol Rep (2010) 12:437–44781% (omeprazole, 20 mg, once in the morning) to 86%
(esomeprazole, 40 mg, once in the morning) in published
clinical trials (our McMaster University database on file).
Nonresponse of erosive esophagitis increases with severity
of erosive esophagitis grading. The healing rate for Los
Angeles grade C and grade D erosive esophagitis on
standard doses of PPIs suggests that about 40% of moderate
(grade C) and 51% of severe (grade D) erosive esophagitis
were not healed after 4 weeks, and 18% of grade C and
27% of grade D were not healed at 8 weeks [11]. An
intragastric pH of at least 4.0 maintained for 16 h is
generally considered the target to promote healing of
erosive esophagitis with antisecretory drugs [12]. Limited
published data show that in healthy volunteers, the time that
pH is less than 3 ranges from 27.8% to 44.1% during the
24-hour period and 36.1% to 65.7% for the nighttime, on
standard doses of PPI after 5 to 8 days [13]. Nonhealing
rates of erosive esophagitis were 26.8% to 34.6% at 4 weeks
and 14.4% to 19.5% at 8 weeks. Any increase in the time
the pH is below 3 in 24 h is associated with an increase in
the proportion of unhealed erosive esophagitis at 8 weeks.
Therefore, the intragastric pH holding time less than 3
might be a suitable predictor for erosive esophagitis
nonhealing; prospective studies are needed [13]. The time
pH is equal to or less than 2 may also predict nonhealing. In
a recent post-hoc analysis of two of our pharmacodynamic
trials, we found that 19% of the 24-hour and 40% of the
midnight to 0700 periods intragastric pH was 2 or less after
esomeprazole, 40 mg, once in the morning for 7 days [14].
Moreover, giving double-dose PPI does not completely
inhibit gastric acid secretion and relieve all persisting reflux
symptoms in patients on PPI. In one report, 16% of patients
had pathologic esophageal pH monitoring despite double-
dose PPI; however, the authors did not define whether
double-dose referred to twice-daily administration [15].
Although PPIs are commonly given twice daily to patients
not responding to once-daily PPI or to those with nocturnal
symptoms, little is known of intragastric pH profiles on
twice-daily PPIs. Based on our meta-analysis, when
standard doses of delayed release-PPIs are given twice
daily in healthy volunteers for 5 to 8 days, 24-hour median
pH reaches at least 4.6. However, pH for up to one third of
the nighttime was less than 4 (15%–36% of the time) and
less than 3 (5%–28% of the time). Esomeprazole, 40 mg,
twice daily in healthy volunteers still resulted in 15% of the
nighttime with intragastric pH less than 4 [16]. Thus, in
patients with reflux, this period of acidification is still some
fourfold longer than the Johnson–DeMeester criteria for
acid reflux.
Most patients will experience reflux after midnight,
when the supine time is associated with more reflux events
[17], and even delayed-release PPIs given twice daily may
still not control nighttime acidity. About 60% to 80% of
patients have persistent gastric acidity at night despite
twice-daily PPIs [18], and about 25% of reflux patients fail
to respond to a twice-daily PPI for 4 to 8 weeks [19]. No
clinical trial has yet compared twice-daily versus once-daily
PPI for patients with NERD.
These findings may explain the increasing number of
reports indicating that as many as 40% of patients with
GERD are not fully satisfied with their antireflux therapy,
and about 20% require a PPI twice daily in an attempt to
control acid secretion in the later part of the day or at night
to heal severe esophagitis or relieve symptoms [20].
Similarly, Chey et al. [21] found that a higher proportion
of those with nighttime symptoms took prescription PPIs
twicedaily(24.3%vs12.7%,P=0.008) and were more likely
to supplement their PPIs with other GERD medications
(45.5% vs 27.9%, P=0.003).
Sleep difficulty increased with nighttime symptom
severity (OR, 3.88 for moderate severity and 13.95 for
severe/very severe when compared with those with slight
severity). Most GERD patients receiving PPIs report
nighttime symptoms, with about half having sleep impairment.
The risk of sleep impairment and work loss increases with
GERD nighttime symptom severity [21].
A US Gallup survey of 1,000 adults experiencing
frequent heartburn found that of the 79% of responders
with nighttime heartburn, 75% reported disturbed sleep and
over-the-counter medications were “: largely ineffective”
[22]. Although the precise role of nocturnal acidification is
not clear, the relationship emphasizes the importance of
pharmacologic nocturnal acid control [23￿].
These areas of unmet medical needs highlight where
more effective acid suppression would bring benefit to
patients. Thus, 24-hour pH control is suboptimal in about
40% of patients, leading to continuing symptoms and slow
or poor healing in grade C and grade D GERD, frequent
dosing is necessary for NSAID protection, and triple
therapy is still required for H. pylori eradication.
Improving the Design of PPIs: Long-Lasting PPIs
and K-Competitive Acid Blockers
The ideal parietal cell acid-blocking agent would possess
either plasma half-life kinetics to permit full 24-hour
inhibition of H,K-ATPase or the ability to block H,K-
ATPase in either the inactive or active state. Therefore, we
focus on the development of such agents.
Tenatoprazole
Tenatoprazole is an imidazo-pyridine. This results in a
fairly normal primary pKa but a marked reduction in
secondary pKa. The rate of activation of this compound to
Curr Gastroenterol Rep (2010) 12:437–447 441the active intermediates is slower than those of omeprazole,
lansoprazole, and rabeprazole (Fig. 5)[ 24]. Slow activation
of tenatoprazole enables tenatoprazole binding to Cys822,
which is located in the membrane domain, giving truly
irreversible inhibition [25, 26].
Tenatoprazole has a much slower metabolism than
omeprazole, lansoprazole, and rabeprazole, giving a plasma
half-life of about 6 h (Fig. 6). The longer plasma half-life of
tenatoprazole, combined with its ability to bind to Cys822,
provides longer inhibition of gastric acid secretion.
The patent on the core structure of tenatoprazole was
extended by synthesis of the S-enantiomer, with superior
pharmacokinetics. Early human studies have shown that
administration of tenatoprazole, 40 mg, at night provides
superior acid control compared to esomeprazole, and better
daytime control [27, 28].
Extended Release of PPIs
Using a formulation technology delaying drug release, a
longer duration of effective plasma concentration of the
drug dexlansoprazole is the (R)-enantiomer of lansoprazole,
(R)-(+)-2-([3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]
methylsulfinyl)-1H-benzo[d]imidazole. Dexlansoprazole
MR is a novel dual delayed-release formulation of
dexlansoprazole approved by the FDA for the treatment of
acid-related disorders. Dexlansoprazole MR extends drug
exposure and somewhat prolongs pH control compared with
lansoprazole (Fig. 7).
In a pharmacokinetic study of dexlansoprazole MR, the
plasma concentration of dexlansoprazole was characterized
by two distinct peaks and a prolonged drug exposure during
the 24-hour dosing interval. Maximum concentration
(Cmax) was achieved at 4 to 4.5 h after administration of
dexlansoprazole MR. Approximate dose proportionality was
observed for mean peak plasma concentration (> 100 ng/mL)
and area under the plasma-concentration time curve after
administration of dexlansoprazole MR.
Doses of dexlansoprazole MR generally produced
greater gastric acid suppression than lansoprazole. Based
on the exposure-response analysis using combined data
from two trials [29], the predicted mean 24-hour intragastric
pH values were 4.06 for the dexlansoprazole MR, 30-mg
dose, and 4.35 for the dexlansoprazole MR, 90-mg dose.
The percent of time pH greater than 4 over 24-hour values
were 59.2% for dexlansoprazole MR, 30 mg, and 66.7% for
dexlansoprazole MR, 90 mg. No appreciable additional gain
in the pharmacodynamic response was predicted for dexlan-
soprazole MR, 120 mg, and thus this dose was not approved
by the FDA for treatment of GERD [29].
A study of the efficacy and safety of dexlansoprazole
MR in healing erosive esophagitis showed better healing
rates than lansoprazole [30￿]. Dexlansoprazole MR, 90 mg,
healed 92% to 95% of patients in individual studies versus
86% to 92% for lansoprazole, using life-table analysis. In
an integrated analysis of 8-week healing in patients with
moderate-to-severe erosive esophagitis, dexlansoprazole
MR, 90 mg, was superior to lansoprazole. All treatments
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442 Curr Gastroenterol Rep (2010) 12:437–447effectively relieved symptoms and were well-tolerated.
Dexlansoprazole MR is highly effective in healing erosive
esophagitis and offers benefits over lansoprazole, particu-
larly in moderate-to-severe disease [30￿]. Another study
with a large number of patients confirmed these results
[31]. Patients (N=451) with erosive esophagitis that was
healed in either of two dexlansoprazole MR healing trials
randomly received dexlansoprazole MR, 60 or 90 mg, or
placebo once daily in this double-blind trial. The percentage
of patients who maintained healing at month 6 was
analyzed using life-table and crude-rate methods. Secondary
endpoints were percentages of nights and of 24-hour days
without heartburn based on daily diaries. Maintenance rates
were 87% for the 60-mg dose and 82% for the 90-mg dose,
versus 26% for placebo (life table), and 66% for the 60-mg
dose and 65% for the 90-mg dose, versus 14% (crude rate).
Both doses were superior to placebo for the percentage of 24-
hour heartburn-free days (60 mg, 96%; 90 mg, 94%; placebo,
19%) and nights (60 mg, 98%; 90 mg, 97%; placebo, 50%).
Alevium (AGN201904-Z)
In an effort to develop a PPI that possessed longer plasma
dwell time, a novel compound, Alevium (AGN201904-Z;
Alevium Pharmaceuticals, Encinitas, CA), was synthesized.
This compound is a prodrug form of omeprazole that
provides a longer plasma dwell time because, unlike all
other PPIs, it is slowly absorbed throughout the small
intestine and not just in the duodenum. Of various derivatives
tested, a sulfonamide derivative—the phenoxyacetic acid
sodium salt derivative of omeprazole—is a candidate drug
with several desirable properties. Its structure is shown in
Fig. 8.
Because one of the benzimidazole nitrogens is substituted,
the compound is acid-stable, unlike any other PPI, and
therefore does not require enteric coating. Furthermore, it is
neutral pH-stable, thus not requiring alkaline solutions for
stability in intravenous formulation, distribution, or adminis-
tration. It is slowly absorbed throughout the small intestine,
but then is rapidly hydrolyzed in the blood to omeprazole and
M
e
d
i
a
n
 
p
H
0
4
5
6
8
7
1
2
3
8h30 14h30 20h30 2h30
Day and time
8h30 14h30 20h30 2h30 8h30
Treatments:
Tenatoprazole, 40 mg
Esomeprazole, 40 mg
Day 1 Day 2 Day 3
Fig. 6 Profile of the median pH
curves over 48 h comparing
esomeprazole with tenatoprazole.
Improvement is seen in pH
control with tenatoprazole, but
stillwithseveralexcursionstopH
<4.0.D1—first day; D2—second
day; E40 mg—esomeprazole,
40 mg; T40 mg—tenatoprazole,
40 mg. (Data from Galmiche
et al. [28].)
C
o
n
c
e
n
t
r
a
t
i
o
n
,
 
n
g
/
m
L
0
800
1000
1200
2000
1600
1800
1400
200
400
600
048 1 2
Time, h
16 20 24
Dexlansoprazole MR, 60 mg QD
Dexlansoprazole MR, 90 mg QD
Dexlansoprazole MR, 120 mg QD
Lansoprazole MR, 30 mg QD
C
o
n
c
e
n
t
r
a
t
i
o
n
,
 
n
g
/
m
L
0
800
1000
1200
2000
1600
1800
1400
200
400
600
048 1 2
Time, h
16 20 24
Dexlansoprazole MR, 30 mg QD
Dexlansoprazole MR, 60 mg QD
Lansoprazole MR, 15 mg QD
A
B
Fig. 7 Mean plasma concentration–time profiles of dexlansoprazole
and lansoprazole on day 5 in study 1 a and study 2 b QD—once daily.
(Data from Vakily et al. [29].)
Curr Gastroenterol Rep (2010) 12:437–447 443the sulfonic acid. Only trace quantities of the intact molecule
are ever found in humans, hence its safety profile should
resemble that of omeprazole. Figure 9 shows the pharmaco-
kinetic profile in human volunteers following administration
of Alevium (AGN201904-Z), 600 mg, and illustrates the
longer residence time above 50 ng/mL from Alevium
compared to esomeprazole [32￿]. Moreover, the longer
residence time does not generate a greater Cmax,a sw o u l d
be the case with high-dose native PPIs.
Figure 9 shows prolongation of the residence time of
omeprazole in the blood, so that drug is present at
inhibitory levels over 24 h after 5 days administration.
This finding leads to considerable improvement in the
profile of intragastric pH (Fig. 10).
With once-daily Alevium (AGN201904-Z), the pH is
stably maintained at greater than 4.0. Averaging pH
values over 24 h or at night shows the remarkable
advantage of Alevium, not only at night, but also during
the day [32￿].
Potassium-Competitive Acid Blockers
Drugs of this class of inhibitor block acid pumping by K
+
competitive inhibition, so this class is called either acid
pump antagonists or potassium-competitive acid blockers
(P-CABs). The first core structure of a P-CAB developed in
1980 s was an imidazo-pyridine. A typical structure of this
class having excellent inhibitory activity is SCH28080.
Later, many P-CABs were developed, some of which are
shown in Fig. 11.
Because P-CAB inhibits the acid pump enzyme by K
+
competition, P-CABs do not require acid-activation. Therefore,
the inhibition by P-CABs is expected to be fast and effective.
Data in humans show rapid and virtually complete inhibition
by P-CABs. For example, in healthy volunteers, high doses of
the compound AZD0865 resulted in more than 95% inhibition
of acid secretion within 1 h after oral administration [33]. This
inhibitor exhibits a classical (sigmoid) dose-response profile,
with the magnitude and duration of effect determined by dose,
pKa, and plasma half-life. AZD0865 demonstrated a dose-
effect relationship with a dose-dependent duration of inhibition
of acid secretion; more than 95% inhibition was sustained for
u pt o1 5hf o r0 . 8a n d1m g / k gd o s e s[ 33]. Surprisingly, even
though AZD0865 provided a faster onset of acid inhibition
with a dose-dependent duration of activity, a clinical study
using once-daily administration showed no clinical benefit over
esomeprazole [34￿, 35]. In a study of a randomized,
comparative trial of AZD0865 and esomeprazole for the
treatment of patients with NERD, using a total of 1469
patients, AZD0865 did not provide clinical benefit over
esomeprazole, 20 mg, in the management of patients with
NERD [34￿]. However, increasing the frequency of adminis-
tration of AZD0865 to twice daily would be expected to
outperform currently approved PPIs. Of particular relevance is
the finding that about 20% of patients continue to experience
symptoms even with twice-daily administration of any PPI.
This finding is largely the result of de novo pump synthesis
occurring after the drug has dropped below threshold in the
blood, about 90 min after administration. A P-CAB with a long
half-life would still be present and more effective than a PPI.
A fused-ring system is soraprazan. Soraprazan inhibited
H,K-ATPase with IC50 of 0.1 μM, Ki of 6.4 nM, and Kd of
26.4 nM [36]. However, no detailed clinical data are
available for this compound.
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Fig. 9 Mean plasma concentration-time profiles of Alevium (AGN
201904-Z) and esomeprazole from two separate trials evaluating at a
day 1 and b day 5. (Data from Hunt et al. [32￿])
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Fig. 8 Chemical structure of Alevium (AGN 201904-Z; Alevium
Pharmaceuticals, Encinitas, CA)
444 Curr Gastroenterol Rep (2010) 12:437–447A new type of P-CAB is being developed by Takeda
Pharmaceuticals (Osaka, Japan) [37]. One of the typical
structures is shown in Fig. 9. Some of these (hetero)
arysulfonylpyrrole compounds showed an IC50 value of 9
to 30 nM. Among them, TAK-438 has been extensively
studied. In rats, TAK-438 at a dose of 4 mg/kg, orally,
completely inhibited gastric acid secretion, giving a higher
pH of gastric perfusate than did SCH28080. Also, the
inhibition by TAK-438 was sustained longer than either
lansoprazole or SCH28080 [38]. This compound is still in
phase 2 trials.
Conclusions
Despite the overall effectiveness of the current PPIs, many
important clinical needs remain unmet, with more than 20%
of patients with GERD experiencing recalcitrant symptoms,
even when taking their drug twice daily. This finding is
essentially a result of the short plasma residence time and
lack of effect during the later part of the day and especially
at night, which cannot be overcome by increasing the dose
or frequency. Although the unmet clinical needs are
discussed here for GERD, the unmet needs are similar for
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Curr Gastroenterol Rep (2010) 12:437–447 445the optimal management of nonvariceal upper GI bleeding,
NSAID gastropathy, and H. pylori eradication, and emanate
from the same pharmacologic shortcomings described in
this review.
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